Cytoreductive Surgery for Peritoneal Carcinomatosis from Endometrial Cancer - A Case Report and Literature Review
|
|
- Moses Todd
- 5 years ago
- Views:
Transcription
1 : Copyright Celsius Case Report Cytoreductive Surgery for Peritoneal Carcinomatosis from Endometrial Cancer - A Case Report and Literature Review N. Bacalbaæa 1, C. Anghel 2, I. Barbu 2, I. Dudus 2, M.I. Ionescu 2, M. Pautov 2, M. Motthor 2, Irina Bãlescu 3, V. Braæoveanu 2,4 1 Carol Davila University of Medicine and Pharmacy Bucharest, Romania 2 Dan Setlacec Department of General Surgery and Liver Transplantation Fundeni Clinical Institute, Bucharest, Romania 3 Ponderas Hospital, Bucharest, Romania 4 Titu Maiorescu University, Faculty of Medicine, Bucharest, Romania REZUMAT Citoreducåie chirurgicalã pentru carcinomatoza peritonealã din cancerul endometrial - prezentare de caz æi revizia literaturii Neoplasmul de endometru reprezintã una din cele mai fercvente malignitati ale tractului genital feminin, prezentând incidenåã în creætere mai ales din cauza cresterii numarului de persoane supraponderale. În timp ce cazurile diagnosticate æi operate în stadii precoce ale bolii au evoluåie favorabilã, lucrurile stau cu totul altfel în cazurile diagnosticate în stadii avansate. În orice caz, pacientele care prezintã diseminãri peritoneale la momentul diagnosticului beneficiazã de un abord chirurgical agresiv, similar cu cel practicat în neoplasmul ovarian avansat. Prezentãm cazul unei paciente de 67 ani diagnosticatã cu carcinomatozã peritonealã de origine endometrialã la care principiile chirurgiei citoreductive au fost aplicate cu success. Cuvinte cheie: neoplasm endometrial, carcinomatozã peritonealã, citoreducåie ABSTRACT Endometrial cancer is one of the most common malignancies of the female reproductive tract, with increasing incidence particularly due to the increase proportion of the overweight persons. While cases diagnosed in an early stage of the disease report an excellent outcome, things significantly change when it comes to advanced stages. However it seems that women who already present peritoneal seeding at the moment of diagnosis benefit most from an aggressive surgical approach, similar to the one performed in advanced stage ovarian cancer. We present the case of a 67 year old patient diagnosed with peritoneal carcinomatosis from endometrial cancer in which the principles of cytoreductive surgery were successfully applied. Key words: endometrial cancer, peritoneal carcinomatosis, cytoreductive surgery Corresponding author: Nicolae Bacalbaæa, MD Dimitrie Racoviåã Street, no. 2, Bucharest, Romania nicolae_bacalbasa@yahoo.ro
2 Cytoreductive Surgery for Peritoneal Carcinomatosis from Endometrial Cancer 173 INTRODUCTION Endometrial cancer is one of the most common malignancies of the genital tract in women, with an increasing incidence in the last few years. The reported incidence in the United States surpassed cases/year while the death rate reached almost 7500 deaths/year (1,2). The most important prognostic factors are thought to be diabetes, estrogen secreting tumors, nulliparity and the higher number of overweight persons (2). While up to 70% of patients are diagnosed in an early stage of the disease and report an excellent outcome (5 year overall survival of 90%), patients diagnosed in an advanced stage of the disease have a poor prognosis associated with low rates of survival - 67% and 23%, respectively, for cases with regional or distant disease (3). However, in these cases it seems that an aggressive surgical approach similar to the one performed in advanced ovarian cancer is perfectly justified (2,4). Figure 1. Initial aspect disseminated peritoneal tumors associated with an uterine tumor CASE REPORT A 67 year old, nulligesta, nullipara, obese patient presented for abdominal and pelvic diffuse pain associated with vaginal bleeding. Local examination revealed the presence of a distended slightly painful abdomen, with no palpable tumor mass. A bioptic uterine curettage was performed and the histopathological findings revealed a poorly differentiated endometrial adenocarcinoma. Abdomino-pelvic computed tomography revealed the presence of disseminated tumor masses all over the peritoneal surface. The patient was submitted to surgery; intraoperatively a large uterine tumor and diffuse peritoneal carcinomatosis were found, so the patient was operated according to the principles of ovarian cytoreductive surgery. A radical total hysterectomy en bloc with bilateral adnexectomy, total omentectomy, total colectomy, pelvic and parietal peritonectomy, pelvic and lymph node dissection were performed (Fig. 1-9). The histopathological findings confirmed the presence of a poorly differentiated endometrial adenocarcinoma. DISCUSSIONS The efficacy of debulking surgery and minimal residual disease after cytoreductive surgery in ovarian cancer encouraged the surgeons to apply the Figure 2. Cmplete mobilization of the uterine body Figure 3. Tumoral nodules involving the mesosigmoid same principles in other advanced abdominal malignancies in order to obtain a better outcome in
3 174 N. Bacalbasa et al Figure 4. Tumoral nodules involving the transverse mesocolon Figure 5. Performing parietal peritonectomy Figure 6. The final aspect after resection, pelvic and para-aortic lymph node dissection Figure 7. Parietal peritonectomy Figure 9. The specimens: total hysterectomy with bilateral adnexectomy, total colectomy and total omentectomy Figure 8. The final aspect of the pelvic cavity after resection
4 Cytoreductive Surgery for Peritoneal Carcinomatosis from Endometrial Cancer 175 terms of survival. Several studies demonstrated the efficacy of cytoreductive surgery associated with other therapeutic strategies such as hypertermic intraperitoneal chemotherapy (HIPEC) in colon cancer and endometrial cancer (2, 4-6). Delotte et al included in their study 13 patients diagnosed with advanced stage endometrial cancer with peritoneal disseminations who were submitted to complete resection and HIPEC. During cytoreductive surgery, an average of 2 organs were resected, the most frequently performed resections being bowel resection, atypical hepatectomies, splenectomies, partial cystectomy or partial frenectomy. They reported a disease free survival of 11,4 months and a median overall survival of 19,4 months. An important conclusion of this study was that association of HIPEC was able to offer a significant increase of survival when compared to cytoreduction alone (19,4 months vs. 12 months) (2). Some other studies also consider that aggressive cytoreduction remains the most important prognostic factor related to an increased overall survival, while other authors consider that the evolution of these cases in strongly correlated to histopathological features and to the initial extent of the disease (7,8). Bakrin et al reported a case series of 5 patients with advanced endometrial cancer with peritoneal carcinomatosis treated by the same principles and reported improved outcomes: 2 patients were free of disease after 2 and 3 years while the other 2 patients were living with recurrence after 1 and 3 years (4). Abu Zaid et al included in their study 6 patients diagnosed with advanced stage endometrial cancer who were treated by cytoreductive surgery and HIPEC from November 2010 to August Cytoreductive surgery consisted of peritonectomy and visceral resections in order to provide a complete elimination of the tumor masses from the abdomino-pelvic Cavity while HIPEC was performed with Cisplatin and Doxorubicin at 41 to 42,2 C for 90 minutes. Postoperatively all patients were submitted to systemic chemotherapy based on carboplatin and paclitaxel regimens. Two cases developed recurrent disease during the next 6 months, one of them being dead because of the disease 5 months after surgery, while the other 4 patients were alive and free of any recurrence at 7,34,35 and 19 months (9). There are authors who consider that endometrial cancer consist in fact of two different tumor types: type 1 endometrial cancer has a primary lymphatic spread by pelvic lymph nodes especially obturatory fossa lymph nodes and only secondarily to iliac lymph nodes, while type 2 has a peritoneal pattern of spread (10). According to these two different patterns of spread, studies have shown that for type 1 stage IV endometrial cancer complete debulking can be achieved only in 44-72% and only patients with good biological status should be candidates for this surgical approach (11,12,13). Bristow et al conducted a study on 65 patients diagnosed with advanced endometrial cancer who were submitted to surgery between January 1990 and December Complete R0 cyotreduction was defined as the absence of residual disease larger than 1 cm; they demonstrated that the overall survival was significantly higher in cases submitted to R0 resection (34,3 months) when compared to those with >1 cm residual disease (11 months, p=0,0001). Other factors associated with improved outcomes were higher performance status, age under 58 years, adjuvant chemo-irradiation. On multivariate analysis age (p=0,023), performance status (p=0,043) and residual disease (p=0,0001) were independent predictors of survival (13). When it comes to patients in whom type 2 stage IV endometrial cancer is encountered, it seems that this subtype resembles most with advanced ovarian cancer and its propagation via transperitoneal route; in consequence, these patients should benefit most from an aggressive surgical approach similar with debulking surgery in advanced stage ovarian cancer (14-21). In order to increase the rate of complete cytoreduction some authors recommended the administration of 3 cycles of neo-adjuvant chemotherapy (22); however patients who report a poor response to neoadjuvant treatment might also not benefit from cytoreductive surgery too (23). When it comes to association of adjuvant treatments such as radiotherapy, studies have shown that it might be useful in the postoperative course. Administrated pre-operatively, radiation therapy seems to interfere with the adequate tumor staging without improving the outcomes (23,24). In order to increase the overall survival, adjuvant chemotherapy can be associated; most authors sustain the association of taxanes- platinum salts regimens (25-27). Randall et al included in their study 388 patients diagnosed with stage IV endometrial cancer who were submitted first to cytoreductive surgery (with maximum residual disease < 2 cm); after surgery, the patients were randomly assigned to doxorubicin and cisplatin chemotherapy for seven courses or
5 176 N. Bacalbasa et al whole-abdominal radiotherapy with 30 Gy in 20 fractions and a pelvic boost of 15 Gy. Although the recurrence rate was similar (55%) in the pelvis and abdomen in both groups, 2-year progression-free survival was better with chemotherapy (59% vs 46%) as was the overall survival (70% vs 59%; p_0 01) (27). However, the largest meta-analysis conducted on the subject of advanced stage endometrial cancer and recurrent endometrial cancer, performed by Barlin et al on 14 studies came to demonstrate that improved survival was positively associated with complete surgical cytoreduction (each 10% increase improved survival by 9.3 months, p = 0.04) and receiving postoperative radiation therapy (each 10% increase improved survival by 11.0 months, p= 0.004); the same meta-analysis concluded that an increasing proportion of patients receiving chemotherapy was negatively associated with survival (each 10% increase decreasing survival by 10.4 months, p= 0.007) (28). CONCLUSIONS The most appropriate therapeutic protocol in advanced endometrial cancer is not well established due to the paucity of data and due to the limited number of patients included in the studies published on this topic so far. However, almost all studies come to sustain the benefit of cytoreductive surgery as part of an aggressive surgical approach; similarly to advanced ovarian cancer, in advanced endometrial cancer one of the most important prognostic factors is the absence of macroscopic residual disease at the end of resection. Other therapies such as HIPEC seem to improve the outcomes without increasing the early postoperative morbidity and mortality. Association of adjuvant chemo-irradiation might also play a role but further studies are still needed. REFERENCES 1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin 2008;58: Delotte, J., Desantis, M., Frigenza, M., Quaranta, D., Bongain, D., Benchimol, D., Bereder, J., Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of endometrial cancer with peritoneal carcinomatosis. European Journal of Obstetrics & Gynecology and Reproductive Biology 172 (2014) Uterine Neoplasms. Practice guidelines in oncology. Network (NCCN): National Comprehensive Cancer; Bakrin N, Cotte E, Sayag-Beaujard A, et al. Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of recurrent endometrial carcinoma confined to the peritoneal cavity. Int J Gynecol Cancer 2010;20: Weber T, Roitman M, Link KH. Current status of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from colorectal cancer. Clin Colorectal Cancer 2012;11: Pomel C, Ferron G, Lorimier G, et al. Hyperthermic intraperitoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study. Eur J Surg Oncol 2010;36: [5] 7. Tanioka M, Katsumata N, Sasajima Y, et al. Clinical characteristics and outcomes of women with stage IV endometrial cancer. Med Oncol 2010; 27: Einstein MH, Rice LW. Current surgical management of endometrial cancer. Hematol Oncol Clin North Am 2012;26: Abu-Zaid A, Azzam AZ, AlOmar O, Salem H, Amin T, Al-Badawi IA, Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for managing peritoneal carcinomatosisfrom endometrial carcinoma: a single-center experience of 6 cases, Ann Saudi Med Mar-Apr;34(2): doi: / Benedetti-Panici P, Maneschi F, Cutillo G, et al. Anatomical and pathological study of retroperitoneal nodes in endometrial cancer. Int J Gynecol Cancer 1998; 8: Goff B, Goodman A, Muntz H, et al. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 1994; 52: Chi D, Welshinger M, Venkatraman E, Barakat R. The role of surgical cytoreduction in stage IV endometrial carcinoma. Gynecol Oncol 1997; 67: Bristow R, Zerbe M, Rosensheim N, et al. Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival. Gynecol Oncol 2000; 78: Slomovitz BM, Burke TW, Eifel PJ, et al. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003; 91: Goff B, Goodman A, Muntz H, et al. Surgical stage IV endometrial carcinoma: a study of 47 cases. Gynecol Oncol 1994; 52: Abeler V, Vergote I, Kjorstad K, Tropé C. Clear cell carcinoma of the endometrium: prognosis and metastatic spread pattern. Cancer 1996; 78: Podratz K, Mariani A. Uterine papillary serous carcinomas: the exigency for clinical trials. Gynecol Oncol 2003; 91: Huh W, Powell M, Leath C, et al. Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy. Gynecol Oncol 2003; 91: Trimbos B, Vergote I, Bolis G, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer- Adjuvant Chemo Therapy in Ovarian Neoplasm Trial. J Natl Cancer Inst 2003; 95: Ramirez-Gonzales C, Adamsons K, Mangual-Vazquez T, et al. Papillary adenocarcinoma in the endometrium. Obstet Gynecol 1987; 70: Cirisano F, Robboy S, Dodge R, et al. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 1999; 74: Geisler JP, Geisler HE, Melton ME, et al. What staging surgery should be performed on patients with uterine papillary serous carcinoma? Gynecol Oncol 1999; 74: Despierre E, Moerman P, Vergote I, Amant F. Is there a role for neoadjuvant chemotherapy in the treatment of stage IV uterine papillary serous carcinoma? Int J Gynecol Cancer (in press). 23. Amant, F., Moerman, P., Neven, P., Timmerman, D., Van Limbergen, E., Vergote, I., Endometrial cancer, com Vol 366 August 6, Einhorn N, Trope C, Ridderheim M, Boman K, Sorbe B, Cavallin Stahl E. A systematic overview of radiation therapy effects in uterine cancer (corpus uteri). Acta Oncol 2003; 42: Fleming G, Brunetto V, Cella D. et al. Phase III trial of doxorubicin plun cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2004; 22: Hoskins P, Swenerton K, Pike J, Wong F, Acquino-Parsons C, Lee N. Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study. J Clin Oncol 2001; 19: Randall ME, Brunetto G, Muss HB, et al. Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma: a randomized phase III trial of the Gynecologic Oncology Group. Proc Am Soc Clin Oncol 2003; 22: Barlin, J., Puri, I., Bristow, R. Cytoreductive surgery for advanced or recurrent endometrial cancer: A meta-analysis; Gynecologic Oncology 118 (2010) 14 18
Prof. Dr. Aydın ÖZSARAN
Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid
More informationNormal Size Ovary Carcinoma Syndrome with Inguinal Ovarian Cancer Lymph Node Metastases A Case Report and Literature Review
doi:10.21873/invivo.11250 Normal Size Ovary Carcinoma Syndrome with Inguinal Ovarian Cancer Lymph Node Metastases A Case Report and Literature Review NICOLAE BACALBASA 1, IRINA BALESCU 2, CRISTIAN BALALAU
More informationTotal Pelvic Exenteration for Locally Invasive Cervical Cancer with Vesico-Vaginal Fistula
: 73-77 Copyright Celsius Case Report Total Pelvic Exenteration for Locally Invasive Cervical Cancer with Vesico-Vaginal Fistula N. Bacalbaæa 1, Irina Bãlescu 2 1 Carol Davila University of Medicine and
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More information7. Cytoreductive surgery in endometrial cancer and uterine sarcomas
Transworld Research Network 37/661 (2), Fort P.O. Trivandrum-695 023 Kerala, India Cytoreductive Surgery in Gynecologic Oncology: A Multidisciplinary Approach, 2010: 123-151 ISBN: 978-81-7895-484-4 Editor:
More informationWinship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer
Winship Cancer Institute of Emory University Optimizing First Line Treatment of Advanced Ovarian Cancer Ira R. Horowitz, MD, SM, FACOG, FACS John D. Thompson Professor and Chairman Department of Gynecology
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationTotal Pelvic Exenteration for Recurrent Endometrial Sarcoma - A Case Report
Chirurgia (2015) 110: 396-400 No. 4, July - August Copyright Celsius Total Pelvic Exenteration for Recurrent Endometrial Sarcoma - A Case Report N. Suciu 1,2, I. Bãlescu 3, N. Bacalbaæa 1 1 Carol Davila
More informationThe role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer
Radiology and Oncology Ljubljana Slovenia www.radioloncol.com research article 341 The role of neoadjuvant chemotherapy in patients with advanced (stage IIIC) epithelial ovarian cancer Erik Škof 1, Sebastjan
More informationCurative anterior pelvic exenteration for pelvic recurrence after irradiated, surgically treated cervical cancer. A case report and literature review
Gineco. [12] 161-165 [2016] DOI: 10.18643/gi.2016.161 @ 2016 Romanian Society of Ultrasonography in Obstetrics and Gynecology Curative anterior pelvic exenteration for pelvic recurrence after irradiated,
More informationPatient Presentation. 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201
Patient Presentation 32 y.o. female complains of lower abdominal mass CEA = 433, CA125 = 201 CT shows: Thickening of the right hemidiaphragm CT shows: Fluid in the right paracolic sulcus CT shows: Large
More informationUTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS
Review Journal of Translational Medicine and Research, volume 19, no. 1-2, 2014 UTERINE SARCOMAS CURRENT THERAPEUTIC OPTIONS N. Bacalbaæa 1, A. Traistaru 2, I. Bãlescu 3 1 Carol Davila University of Medicine
More informationChapter 2: Initial treatment for endometrial cancer (including histologic variant type)
Chapter 2: Initial treatment for endometrial cancer (including histologic variant type) CQ01 Which surgical techniques for hysterectomy are recommended for patients considered to be stage I preoperatively?
More informationIncidence and Clinical Outcomes of Non-endometrioid Carcinoma of Endometrium: Siriraj Hospital Experience
RESEARCH ARTICLE Incidence and Clinical Outcomes of Non-endometrioid Carcinoma of Endometrium: Siriraj Hospital Experience Atthapon Jaishuen 1, Kate Kunakornporamat 1, Boonlert Viriyapak 1, Mongkol Benjapibal
More informationAn Unusual Case of Cervical Cancer with Inguinal Lymph Node Metastasis: A Case Report and Review of the Literature
Archives of Clinical and Medical Case Reports doi: 10.26502/acmcr.9655003 Volume 1, Issue 1 Case Report An Unusual Case of Cervical Cancer with Inguinal Lymph Node Metastasis: A Case Report and Review
More informationOne of the commonest gynecological cancers,especially in white Americans.
Gynaecology Dr. Rozhan Lecture 6 CARCINOMA OF THE ENDOMETRIUM One of the commonest gynecological cancers,especially in white Americans. It is a disease of postmenopausal women with a peak incidence in
More informationOvarian cancer: clinical practice the Arabic perspective
Lead Group Log Ovarian cancer: clinical practice the Arabic perspective Experience of Hôtel-Dieu de France University Hospital (Beirut, LEBANON) in supraradical surgery for ovarian cancer David ATALLAH
More informationStage IVB endometrial cancer confined to the abdomen: is chemotherapy superior to radiotherapy?
European Journal of EJGO Gynaecological Oncology Stage IVB endometrial cancer confined to the abdomen: is chemotherapy superior to radiotherapy? D. Akdag Cirik, A. Karalok, I. Ureyen, T. Tasci, S. Koc,
More informationENDOMETRIAL CANCER. Endometrial cancer is a great concern in UPDATE. For personal use only. Copyright Dowden Health Media
For mass reproduction, content licensing and permissions contact Dowden Health Media. UPDATE ENDOMETRIAL CANCER Are lymphadenectomy and external-beam radiotherapy valuable in women who have an endometrial
More informationC ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)
C ORPUS UTERI C ARCINOMA STAGING FORM CLINICAL Extent of disease before any treatment y clinical staging completed after neoadjuvant therapy but before subsequent surgery Tis * T1 I T1a IA NX N0 N1 N2
More informationEndometrial Cancer. Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines
Saudi Gynecology Oncology Group (SGOG) Gynecological Cancer Treatment Guidelines Endometrial Cancer Emad R. Sagr, MBBS, FRCSC Consultant Gynecology Oncology Security forces Hospital, Riyadh Epidemiology
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationIndex. B Bilateral salpingo-oophorectomy (BSO), 69
A Advanced stage endometrial cancer diagnosis, 92 lymph node metastasis, 92 multivariate analysis, 92 myometrial invasion, 92 prognostic factors FIGO stage, 94 histological grade, 94, 95 histologic cell
More informationNew Cancer Cases By Site Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3%
Uterine Malignancy New Cancer Cases By Site 2010 Breast 28% Lung 14% Colo-Rectal 10% Uterus 6% Thyroid 5% Lymphoma 4% Ovary 3% Cancer Deaths By Site 2010 Lung 26% Breast 15% Colo-Rectal 9% Pancreas 7%
More informationRelapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.9.3861 Relapse Patterns and Outcomes Following Recurrence of Endometrial Cancer in Northern Thai Women RESEARCH ARTICLE Relapse Patterns and Outcomes Following
More informationPOSTERIOR PELVIC EXENTERATION FOR ADVANCED, UNRESPONSIVE TO RADIATION THERAPY CERVICAL CANCER A CASE REPORT
: 196-200 Copyright Celsius Case Report POSTERIOR PELVIC EXENTERATION FOR ADVANCED, UNRESPONSIVE TO RADIATION THERAPY CERVICAL CANCER A CASE REPORT N. Bacalbaæa 1, Irina Bãlescu 2 1 Carol Davila University
More informationMultiple visceral resections for pelvic recurrence from surgically treated clear cell ovarian tumor - a case report
CASE REPORT J. Transl. Med. Res 2015;2(20):113-117 Multiple visceral resections for pelvic recurrence from surgically treated clear cell ovarian tumor - a case report Irina Bălescu 1, Nicolae Bacalbaşa
More informationMarcello Deraco M.D. Responsible Peritoneal Malignancies
Perspectives in clinical research for the treatment of peritoneal carcinomatosisin from ovarian cancer Marcello Deraco M.D. Responsible Peritoneal Malignancies Advisable limits of cytoreduction Survey
More informationINTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC)
UnitedHealthcare Commercial Medical Policy INTRAOPERATIVE HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY (HIPEC) Policy Number: SUR052 Effective Date: January 1, 2019 Table of Contents Page INSTRUCTIONS FOR
More informationSurgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer
Ovarian cancer Surgical management and neoadjuvant chemotherapy for stage III-IV ovarian cancer JM. Classe, R. Rouzier, O.Glehen, P.Meeus, L.Gladieff, JM. Bereder, F Lécuru Suitable candidates for neo-adjuvant
More informationPrognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases
J Gynecol Oncol Vol. 20, No. 3:158-163, September 2009 DOI:10.3802/jgo.2009.20.3.158 Original Article Prognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases
More informationC ORPUS UTERI C ARCINOMA STAGING FORM (Carcinosarcomas should be staged as carcinomas)
CLINICAL C ORPUS UTERI C ARCINOMA STAGING FORM PATHOLOGIC Extent of disease before S TAGE C ATEGORY D EFINITIONS Extent of disease through any treatment completion of definitive surgery y clinical staging
More informationOvarian Cancer Survival. Ovarian Cancer Follow-up. Ovarian Cancer Treatment. Management of Recurrent Ovarian Carcinoma. 15,520 cancer deaths
Management of Recurrent Ovarian Carcinoma Lee-may Chen, M.D. Department of Obstetrics, Gynecology, & Reproductive Sciences UCSF Comprehensive Cancer Center Ovarian Cancer Survival United States, 28: 1
More informationUpdate on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact
Update on Sentinel Node Biopsy in Endometrial Cancer: Feasibility, Technique, Impact Bjørn Hagen, MD, PhD St Olavs Hospital Trondheim University Hospital Trondheim, Norway Endometrial Cancer (EC) The most
More informationAbstract. Materials and methods
Int J Gynecol Cancer 2006, 16, 490 495 Long-term survival in advanced ovarian carcinoma following cytoreductive surgery with standard peritonectomy procedures A.-A.K. TENTES, C.G. MIRELIS, S.K. MARKAKIDIS,
More informationStaging. Carcinoma confined to the corpus. Carcinoma confined to the endometrium. Less than ½ myometrial invasion. Greater than ½ myometrial invasion
5 th of June 2009 Background Most common gynaecological carcinoma in developed countries Most cases are post-menopausal Increasing incidence in certain age groups Increasing death rates in the USA 5-year
More informationReview Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer
Review Heated Intraperitoneal Chemotherapy in the Management of Ovarian Cancer Andrea Jewell 1, Megan McMahon 1 and Dineo Khabele 1 1 Division of Gynecologic Oncology, Department of Obstetrics and Gynecology,
More information3/25/2019. Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates
J. Anthony Rakowski D.O., F.A.C.O.O.G. MSU SCS Board Review Coarse Rare uterine cancers ~3% Leiomyosarcoma Carcinosarcoma (MMMT) Endometrial Stromal Sarcomas Aggressive tumors High Mortality Rates Signs
More informationGynecologic Oncologist. Surgery Chemotherapy Radiation Therapy Hormonal Therapy Immunotherapy. Cervical cancer
Gynecologic Oncology Pre invasive vulvar, vaginal, & cervical disease Vulvar Cervical Endometrial Uterine Sarcoma Fallopian Tube Ovarian GTD Gynecologic Oncologist Surgery Chemotherapy Radiation Therapy
More informationIndex. Surg Oncol Clin N Am 14 (2005) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 14 (2005) 433 439 Index Note: Page numbers of article titles are in boldface type. A Abdominosacral resection, of recurrent rectal cancer, 202 215 Ablative techniques, image-guided,
More informationChemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Find Studies About Studies Submit Studies Resources About Site Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer The safety and scientific validity of this study is
More informationEndometrial Cancer. Incidence. Types 3/25/2019
Endometrial Cancer J. Anthony Rakowski DO, FACOOG MSU SCS Board Review Coarse Incidence 53,630 new cases yearly 8,590 deaths yearly 4 th most common malignancy in women worldwide Most common GYN malignancy
More informationMedical Policy An Independent Licensee of the Blue Cross and Blue Shield Association
Cytoreduction and Hyperthermic Page 1 of 10 Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association Title: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for the
More informationCase Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue
Case Scenario 1 Oncology Consult: Patient is a 51-year-old male with history of T4N3 squamous cell carcinoma of tonsil status post concurrent chemoradiation finished in October two years ago. He was hospitalized
More informationAnshuma Bansal 1 Bhavana Rai
DOI 10.1007/s13224-016-0926-7 ORIGINAL ARTICLE Fractionated Palliative Pelvic Radiotherapy as an Effective Modality in the Management of Recurrent/Refractory Epithelial Ovarian Cancers: An Institutional
More informationMUSCLE-INVASIVE AND METASTATIC BLADDER CANCER
MUSCLE-INVASIVE AND METASTATIC BLADDER CANCER (Text update March 2008) A. Stenzl (chairman), N.C. Cowan, M. De Santis, G. Jakse, M. Kuczyk, A.S. Merseburger, M.J. Ribal, A. Sherif, J.A. Witjes Introduction
More informationMPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?
MPH Quiz Case 1 Surgical Pathology from hysterectomy performed July 11, 2007 Final Diagnosis: Uterus, resection: Endometrioid adenocarcinoma, Grade 1 involving most of endometrium, myometrial invasion
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationClear cell carcinoma arising from abdominal wall endometriosis: a unique case with bladder and lymph node metastasis
Liu et al. World Journal of Surgical Oncology 2014, 12:51 WORLD JOURNAL OF SURGICAL ONCOLOGY CASE REPORT Open Access Clear cell carcinoma arising from abdominal wall endometriosis: a unique case with bladder
More informationPre-operative assessment of patients for cytoreduction and HIPEC
Pre-operative assessment of patients for cytoreduction and HIPEC Washington Hospital Center Washington, DC, USA Ovarian Cancer Surgery New Strategies Bergamo, Italy May 5, 2011 Background Cytoreductive
More informationBACKGROUND: STUDY DESIGN: RESULTS: CONCLUSIONS: Disclosure Information: Nothing to disclose.
Surgical Procedures and Morbidities of Diaphragmatic Surgery in Patients Undergoing Initial or Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Sebastien Gouy, MD, Elisabeth Chereau, MD, Ana
More informationCytoreductive Surgery for Advanced Epithelial Tumors of the Ovary: Technical Considerations and Outcome
Journal of the Egyptian Nat. Cancer Inst., Vol., No. 3, September: -, Cytoreductive Surgery for Advanced Epithelial Tumors of the Ovary: Technical Considerations and Outcome EL-SAYED ASHRAF KHALIL, M.D.*;
More informationCytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease. Results of the French multicentric database
Cytoreductive surgery and perioperative intraperitoneal chemotherapy for Rare Peritoneal Disease Results of the French multicentric database Université Lyon 1 Centre Hospitalo-Universitaire Lyon-Sud EA
More informationStaging and Treatment Update for Gynecologic Malignancies
Staging and Treatment Update for Gynecologic Malignancies Bunja Rungruang, MD Medical College of Georgia No disclosures 4 th most common new cases of cancer in women 5 th and 6 th leading cancer deaths
More informationAdjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 10-year Survivals
6 Adjuvant Chemotherapy in High Risk Patients after Wertheim Hysterectomy 0-year Survivals V Sivanesaratnam,*FAMM, FRCOG, FACS Abstract Although the primary operative mortality following radical hysterectomy
More informationENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
More informationTOC NCCN Categories of Evidence and Consensus Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. Category 2A: Based upon lower-level evidence,
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year
More informationARROCase: Locally Advanced Endometrial Cancer
ARROCase: Locally Advanced Endometrial Cancer Charles Vu, MD (PGY-3) Faculty Advisor: Peter Y. Chen, MD, FACR Beaumont Health (Royal Oak, MI) November 2016 Case 62yo female with a 3yr history of vaginal
More informationImpact of Surgery Extent on Survival and Recurrence Rate of Stage ⅠEndometrial Adenocarcinoma
Hou et al. / Cancer Cell Research 3 (2014) 65-69 Cancer Cell Research Available at http:// http://www.cancercellresearch.org/ ISSN 2161-2609 Impact of Surgery Extent on Survival and Recurrence Rate of
More informationPort-Site Metastases After Robotic Surgery for Gynecologic Malignancy
SCIENTIFIC PAPER Port-Site Metastases After Robotic Surgery for Gynecologic Malignancy Noah Rindos, MD, Christine L. Curry, MD, PhD, Rami Tabbarah, MD, Valena Wright, MD ABSTRACT Background and Objectives:
More information10. Ovarian Cancer. Introduction
10. Ovarian Cancer Introduction In 2000, 826 new cases of ovarian cancer were diagnosed in Sweden making it the fifth most common cancer in women. The median age of newly diagnosed patients was between
More informationAdjuvant Radiotherapy in Endometrial Carcinoma David T. Shaeffer and Marcus E. Randall. doi: /theoncologist
Adjuvant Radiotherapy in Endometrial Carcinoma David T. Shaeffer and Marcus E. Randall The Oncologist 2005, 10:623-631. doi: 10.1634/theoncologist.10-8-623 The online version of this article, along with
More informationTREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS
TREATMENT OF PERITONEAL COLORECTAL CARCINOMATOSIS Anna Lepistö, MD, PhD Department of Colorectal Surgery, Abdominal Center, Helsinki University Hospital Incidence, prevalence and risk factors for peritoneal
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer
THIS DOCUMENT North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT
More informationOvarian cancer experience from a Romanian regional center: preliminary results
Human & Veterinary Medicine International Journal of the Bioflux Society OPEN ACCESS Research Article Ovarian cancer experience from a Romanian regional center: preliminary results 1 Anita-Roxana Maxim,
More informationEpithelial Ovarian Cancer
Epithelial Ovarian Cancer GYNE/ONC Practice Guideline Dr. Alex Hammond Dr. Ian Kerr Dr. Akira Sugimoto Dr. Stephen Welch Kay Faroni Christine Gawlik Kerri Thornton Approval Date: This guideline is a statement
More informationLAPAROSCOPY and OVARIAN CANCER
LAPAROSCOPY and OVARIAN CANCER J. DAUPLAT Clermont-Ferrand France UNIVERSITÉ D'AUVERGNE CLERMONT 1 1 - PROPHYLACTIC OOPHORECTOMY 2 - DIAGNOSIS 3 - EARLY STAGES : STAGING 4 - ADVANCED STAGES - ASSESSMENT
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND
More informationEndometrial cancer in women 45 years of age or younger: A clinicopathological analysis
American Journal of Obstetrics and Gynecology (2005) 193, 1640 4 www.ajog.org Endometrial cancer in women 45 years of age or younger: A clinicopathological analysis Gilbert P. Pellerin, MD, Michael A.
More informationRadiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,700 108,500 1.7 M Open access books available International authors and editors Downloads Our
More informationGynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy
Gynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy Stephanie Yap, M.D. University Gynecologic Oncology Northside Cancer Institute Our Learning Objectives Review survival rates,
More informationHitting the High Points Gynecologic Oncology Review
Hitting the High Points is designed to cover exam-based material, from preinvasive neoplasms of the female genital tract to the presentation, diagnosis and treatment, including surgery, chemotherapy, and
More informationNon-Endometrioid Adenocarcinoma of the Uterine Corpus: A Review of Selected Histological Subtypes
The pathology, epidemiology, prognosis, operative and postoperative management, and research frontiers are reviewed for the most common non-endometrioid endometrial carcinomas. Marguerite Bride. West Cornwall
More informationFrom Research to Practice: What s New in Gynecologic Cancers?
From Research to Practice: What s New in Gynecologic Cancers? David Warshal, M.D. Head, Division of Gynecologic Oncology MD Anderson Cooper Cancer Institute Associate Professor of Obstetrics and Gynecology
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationInvasive Cervical Cancer: Squamous Cell, Adenocarcinoma, Adenosquamous
Note: If available, clinical trials should be considered as preferred treatment options for eligible patients (www.mdanderson.org/gynonctrials). Other co-morbidities are taken into consideration prior
More informationMP Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Medical Policy MP 2.03.07 Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic BCBSA Ref. Policy: 2.03.07 Last Review: 07/25/2018 Effective Date: 07/25/2018
More informationpros and cons
A Gynecologic Oncology Group Study Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: v.s. III GOG Marcus E. Randall,
More informationPlease complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES CASE 1: FEMALE REPRODUCTIVE
Please complete prior to the webinar. HOSPITAL REGISTRY WEBINAR FEMALE REPRODUCTIVE SYSTEM EXERCISES PHYSICAL EXAMINATION CASE 1: FEMALE REPRODUCTIVE 3/5 Patient presents through the emergency room with
More informationAdjuvant treatment, tumour recurrence and the survival rate of uterine serous carcinomas: a single-institution review of 62 women
Adjuvant treatment, tumour recurrence and the survival rate of uterine serous carcinomas: a single-institution review of 62 women Pol F, MD, Department of Obstetrics and Gynaecology, Radboud University
More informationCancer Cervix with Brain Metastasis- A rare case from a Rural center of Maharashtra
Case report Cancer Cervix with Brain Metastasis- A rare case from a Rural center of Maharashtra 1 Dr Khushboo Rastogi, 2 Dr Vandana Jain, 3 Dr Darshana Kawale, 4 Dr Siddharth Nagshet, 5 Dr Gopal Pemmaraju
More informationEndometrial cancer. Szabolcs Máté MD. I. St. Department of Obstetrics and Gyneacology.
Endometrial cancer Szabolcs Máté MD. I. St. Department of Obstetrics and Gyneacology dr.mate.szabolcs@gmail.com Epidemiology Developing countries Cervical cancer is the most common gyn. malignant tumor
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Cytoreductive Surgery and Perioperative Intraperitoneal Page 1 of 26 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Cytoreductive Surgery and Perioperative Intraperitoneal
More informationSquamous cell carcinoma arising in a dermoid cyst of the ovary: a case series
DOI: 10.1111/j.1471-0528.2007.01478.x www.blackwellpublishing.com/bjog Gynaecological oncology Squamous cell carcinoma arising in a dermoid cyst of the ovary: a case series JL Hurwitz, a A Fenton, a WG
More informationBiological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report
ONCOLOGY LETTERS 9: 1239-1243, 2015 Biological intensity-modulated radiotherapy plus neoadjuvant chemotherapy for multiple peritoneal metastases of ovarian cancer: A case report SHIGAO HUANG *, YAZHENG
More information2016 Uterine Cancer Annual Report
2016 Uterine Cancer Annual Report Overview At Carolinas HealthCare System s Levine Cancer Institute, we offer comprehensive care focused on using the latest technology and innovative techniques in the
More informationBeen Diagnosed with Ovarian Cancer, Now What?
Been Diagnosed with Ovarian Cancer, Now What? Teresa P. Díaz-Montes, MD, MPH, FACOG Associate Director, Lya Segall Ovarian Cancer Institute Mercy Medical Center, Baltimore, MD Ovarian Cancer Statistics:
More informationStudy Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus
Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus Investigators Dr Bronwyn King, Peter MacCallum Cancer Centre Dr Linda Mileshkin, Peter MacCallum Cancer Centre
More informationCase Scenario 1. 1/2/13 History: 64-year-old white female presented with right leg swelling and redness, abdominal pain.
Case Scenario 1 1/2/13 History: 64-year-old white female presented with right leg swelling and redness, abdominal pain. 1/02/13 CT Abdomen/Pelvis: Abnormal area of nodular mesenteric and left anterior
More informationCase Scenario 1. 1/2/13 History: 64-year-old white female presented with right leg swelling and redness, abdominal pain.
Case Scenario 1 1/2/13 History: 64-year-old white female presented with right leg swelling and redness, abdominal pain. 1/02/13 CT Abdomen/Pelvis: Abnormal area of nodular mesenteric and left anterior
More informationCytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Select Intra-Abdominal and Pelvic Malignancies
Last Review Status/Date: December 2016 Page: 1 of 29 Intraperitoneal Chemotherapy for Select Intra- Description Cytoreductive surgery (CRS) comprises peritonectomy (ie, peritoneal stripping) procedures
More informationAdvanced Pelvic Malignancy: Defining Resectability Be Aggressive. Lloyd A. Mack September 19, 2015
Advanced Pelvic Malignancy: Defining Resectability Be Aggressive Lloyd A. Mack September 19, 2015 CONFLICT OF INTEREST DECLARATION I have no conflicts of interest Advanced Pelvic Malignancies Locally Advanced
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationSurgical Department, Didimotichon General Hospital, Didimotichon, Greece 2
Hindawi Publishing Corporation Journal of Oncology Volume 22, Article ID 35834, 6 pages doi:.55/22/35834 Clinical Study Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy
More informationGYNECOLOGIC MALIGNANCIES: Ovarian Cancer
GYNECOLOGIC MALIGNANCIES: Ovarian Cancer KRISTEN STARBUCK, MD ROSWELL PARK CANCER INSTITUTE DEPARTMENT OF SURGERY DIVISION OF GYNECOLOGIC ONCOLOGY APRIL 19 TH, 2018 Objectives Basic Cancer Statistics Discuss
More information